JP2023533003A5 - - Google Patents
Info
- Publication number
- JP2023533003A5 JP2023533003A5 JP2023500425A JP2023500425A JP2023533003A5 JP 2023533003 A5 JP2023533003 A5 JP 2023533003A5 JP 2023500425 A JP2023500425 A JP 2023500425A JP 2023500425 A JP2023500425 A JP 2023500425A JP 2023533003 A5 JP2023533003 A5 JP 2023533003A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- pharmaceutically acceptable
- isomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010633550.2 | 2020-07-06 | ||
| CN202010633550.2A CN113896711A (zh) | 2020-07-06 | 2020-07-06 | 杂环类免疫调节剂 |
| PCT/CN2021/102873 WO2022007659A1 (zh) | 2020-07-06 | 2021-06-28 | 杂环类免疫调节剂 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533003A JP2023533003A (ja) | 2023-08-01 |
| JP2023533003A5 true JP2023533003A5 (enExample) | 2024-05-14 |
| JP7712703B2 JP7712703B2 (ja) | 2025-07-24 |
Family
ID=79186707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500425A Active JP7712703B2 (ja) | 2020-07-06 | 2021-06-28 | ヘテロ環式免疫調節物質 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230271933A1 (enExample) |
| EP (1) | EP4177247A4 (enExample) |
| JP (1) | JP7712703B2 (enExample) |
| KR (1) | KR20230037035A (enExample) |
| CN (2) | CN113896711A (enExample) |
| AU (1) | AU2021303635A1 (enExample) |
| CA (1) | CA3189041A1 (enExample) |
| MX (1) | MX2023000382A (enExample) |
| WO (1) | WO2022007659A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| CN120813578A (zh) * | 2023-04-28 | 2025-10-17 | 北京诺诚健华医药科技有限公司 | 杂环类gspt1降解剂 |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3202460T3 (pl) * | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| CA3108974C (en) | 2012-08-09 | 2023-04-04 | Celgene Corporation | Processes for the preparation of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| WO2014116573A1 (en) * | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| ES2963446T3 (es) * | 2015-09-29 | 2024-03-27 | Kangpu Biopharmaceuticals Ltd | Composición farmacéutica y aplicación de la misma |
| CN110506039A (zh) * | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| WO2018140671A1 (en) * | 2017-01-27 | 2018-08-02 | Celgene Corporation | 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof |
| EP4467143B1 (en) * | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| AU2018351050B2 (en) * | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| CN107739389B (zh) | 2017-11-03 | 2020-03-31 | 华东师范大学 | 3位取代的(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮类化合物及其合成方法 |
| KR102718800B1 (ko) * | 2018-05-23 | 2024-10-18 | 셀진 코포레이션 | 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도 |
| CA3106239A1 (en) * | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| WO2020210630A1 (en) * | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
-
2020
- 2020-07-06 CN CN202010633550.2A patent/CN113896711A/zh active Pending
-
2021
- 2021-06-28 CA CA3189041A patent/CA3189041A1/en active Pending
- 2021-06-28 EP EP21838438.6A patent/EP4177247A4/en active Pending
- 2021-06-28 WO PCT/CN2021/102873 patent/WO2022007659A1/zh not_active Ceased
- 2021-06-28 US US18/014,623 patent/US20230271933A1/en active Pending
- 2021-06-28 MX MX2023000382A patent/MX2023000382A/es unknown
- 2021-06-28 JP JP2023500425A patent/JP7712703B2/ja active Active
- 2021-06-28 CN CN202180048474.1A patent/CN115776983A/zh active Pending
- 2021-06-28 KR KR1020237004029A patent/KR20230037035A/ko active Pending
- 2021-06-28 AU AU2021303635A patent/AU2021303635A1/en active Pending